`• Recommended dosage in pediatric patients 3 years and older:
`Recommended dosage of HARVONI in pediatric patients 3 years of
`age and older is based on weight. Refer to Table 2 of the full
`prescribing information for specific dosing guidelines based on body
`weight. (2.4)
`• HCV/HIV-1 coinfection: For adult and pediatric patients with
`HCV/HIV-1 coinfection, follow the dosage recommendations in the
`tables in the full prescribing information. (2.3, 2.4)
`• If used in combination with ribavirin, follow the recommendations for
`ribavirin dosing and dosage modifications. (2.3, 2.4)
`• For patients with any degree of renal impairment, including end
`stage renal disease on dialysis, no HARVONI dosage adjustment is
`recommended. (2.6)
`
`
`-----------------------DOSAGE FORMS AND STRENGTHS--------------------
`• Tablets: 90 mg of ledipasvir and 400 mg of sofosbuvir; 45 mg of
`ledipasvir and 200 mg of sofosbuvir. (3)
`• Oral Pellets: 45 mg of ledipasvir and 200 mg of sofosbuvir; 33.75 mg
`of ledipasvir and 150 mg of sofosbuvir. (3)
`
`
`--------------------------------CONTRAINDICATIONS------------------------------
`If used in combination with ribavirin, all contraindications to ribavirin
`also apply to HARVONI combination therapy. (4)
`
`-------------------------WARNINGS AND PRECAUTIONS----------------------
`• Risk of Hepatitis B Virus Reactivation: Test all patients for evidence
`of current or prior HBV infection before initiation of HCV treatment.
`Monitor HCV/HBV coinfected patients for HBV reactivation and
`hepatitis flare during HCV treatment and post-treatment follow-up.
`Initiate appropriate patient management for HBV infection as
`clinically indicated. (5.1)
`• Bradycardia with amiodarone coadministration: Serious symptomatic
`bradycardia may occur in patients taking amiodarone, particularly in
`patients also receiving beta blockers, or those with underlying
`cardiac comorbidities and/or advanced liver disease.
`Coadministration of amiodarone with HARVONI is not
`recommended. In patients without alternative, viable treatment
`options, cardiac monitoring is recommended. (5.2, 6.2, 7.2)
`
`
`-------------------------------ADVERSE REACTIONS-----------------------------
`• The most common adverse reactions (incidence greater than or
`equal to 10%, all grades) observed with treatment with HARVONI
`were fatigue, headache, and asthenia. (6.1)
`
`
`To report SUSPECTED ADVERSE REACTIONS, contact Gilead
`Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or
`www.fda.gov/medwatch.
`
`---------------------------------DRUG INTERACTIONS---------------------------
`• Coadministration with amiodarone may result in serious
`symptomatic bradycardia. Use of HARVONI with amiodarone is not
`recommended. (5.2, 6.2, 7.2)
`• P-gp inducers (e.g., rifampin, St. John’s wort): May alter
`concentrations of ledipasvir and sofosbuvir. Use of HARVONI with
`P-gp inducers is not recommended. (5.3, 7, 12.3)
`• Consult the full prescribing information prior to use for potential drug
`interactions. (5.2, 5.3, 7, 12.3)
`• Clearance of HCV infection with direct acting antivirals may lead to
`changes in hepatic function, which may impact safe and effective
`use of concomitant medications. Frequent monitoring of relevant
`laboratory parameters (INR or blood glucose) and dose adjustments
`of certain concomitant medications may be necessary. (7.2)
`
`---------------------USE IN SPECIFIC POPULATIONS----------------------
`• Pediatric Use: No data are available regarding the safety of
`HARVONI in pediatric patients with renal impairment. (8.4)
`
`
`See 17 for PATIENT COUNSELING INFORMATION and
`FDA-approved patient labeling.
`
`
`
`
`
`
`
`Revised: 11/2019
`
`HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use
`HARVONI® safely and effectively. See full prescribing information
`for HARVONI.
`
`HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use
`HARVONI® (ledipasvir and sofosbuvir) oral pellets
`Initial U.S. Approval: 2014
`
`
`WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN
`PATIENTS COINFECTED WITH HCV AND HBV
`See full prescribing information for complete boxed warning.
`
`Hepatitis B virus (HBV) reactivation has been reported, in some
`cases resulting in fulminant hepatitis, hepatic failure, and death.
`(5.1)
`
`------------------------------RECENT MAJOR CHANGES -----------------------
`Indications and Usage (1) 8/2019
`Dosage and Administration
` Recommended Treatment Regimen and Duration in
` Patients 3 Years of Age and Older with Genotype 1, 4, 5,
` or 6 HCV (2.2) 8/2019
` Recommended Dosage in Pediatric Patients 3 Years of
` Age and Older (2.4) 8/2019
` Preparation and Administration of Oral Pellets (2.5) 8/2019
` Renal Impairment (2.6)
`
`
`
` 11/2019
`
`-------------------------------INDICATIONS AND USAGE-------------------------
`HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus
`(HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog
`NS5B polymerase inhibitor, and is indicated for the treatment of
`chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years
`of age and older:
`• Genotype 1, 4, 5, or 6 infection without cirrhosis or with
`compensated cirrhosis
`• Genotype 1 infection with decompensated cirrhosis, in combination
`with ribavirin
`• Genotype 1 or 4 infection who are liver transplant recipients without
`cirrhosis or with compensated cirrhosis, in combination with ribavirin.
`(1)
`------------------------DOSAGE AND ADMINISTRATION-----------------------
`• Testing prior to the initiation of therapy: Test all patients for HBV
`infection by measuring HBsAg and anti-HBc. (2.1)
`• Recommended treatment regimen and duration in patients 3 years
`of age and older: (2.2)
`
`HCV
`Genotype
`
`Patient Population
`
`Treatment-naïve without cirrhosis or
`with compensated cirrhosis (Child-
`Pugh A)
`Treatment-experienced without
`cirrhosis
`Treatment-experienced with
`compensated cirrhosis (Child-Pugh A)
`Treatment-naïve and treatment-
`experienced with decompensated
`cirrhosis (Child-Pugh B or C)
`Treatment-naïve and treatment-
`experienced liver transplant recipients
`without cirrhosis, or with compensated
`cirrhosis (Child-Pugh A)
`Treatment-naïve and treatment-
`experienced without cirrhosis or with
`compensated cirrhosis (Child-Pugh A)
`
`Genotype
`1
`
`Genotype
`1 or 4
`
`Genotype
`4, 5, or 6
`
`Regimen
`and
`Duration
`HARVONI
`12 weeks
`HARVONI
`12 weeks
`HARVONI
`24 weeks
`HARVONI
`+ ribavirin
`12 weeks
`HARVONI
`+ ribavirin
`12 weeks
`
`HARVONI
`12 weeks
`
` Recommended dosage in adults: One tablet (90 mg of ledipasvir
`and 400 mg of sofosbuvir) taken orally once daily with or without
`food. (2.3)
`
` •
`
`Reference ID: 4520919
`
`
`
`1
`
`
`
`
`
`
`
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`
`WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN
`PATIENTS COINFECTED WITH HCV AND HBV
`1 INDICATIONS AND USAGE
`2 DOSAGE AND ADMINISTRATION
`
`2.1 Testing Prior to the Initiation of Therapy
`
`2.2 Recommended Treatment Regimen and Duration in
`Patients 3 Years of Age and Older with Genotype 1, 4, 5, or
`6 HCV
`2.3 Recommended Dosage in Adults
`2.4 Recommended Dosage in Pediatric Patients 3 Years of
`Age and Older
`2.5 Preparation and Administration of Oral Pellets
`2.6 Renal Impairment
`3 DOSAGE FORMS AND STRENGTHS
`4 CONTRAINDICATIONS
`5 WARNINGS AND PRECAUTIONS
`
`5.1 Risk of Hepatitis B Virus Reactivation in Patients
`Coinfected with HCV and HBV
`5.2 Serious Symptomatic Bradycardia When Coadministered
`with Amiodarone
`5.3 Risk of Reduced Therapeutic Effect Due to Use with P-gp
`Inducers
`5.4 Risks Associated with Ribavirin Combination Treatment
`
`6 ADVERSE REACTIONS
`
`6.1 Clinical Trials Experience
`
`6.2 Postmarketing Experience
`7 DRUG INTERACTIONS
`
`7.1 Potential for Drug Interaction
`
`7.2 Established and Potentially Significant Drug Interactions
`
`7.3 Drugs without Clinically Significant Interactions with
`HARVONI
`
`
`
`
`
`
`
`
`
`Reference ID: 4520919
`
`
`
`8 USE IN SPECIFIC POPULATIONS
`
`8.1 Pregnancy
`
`8.2 Lactation
`
`8.3 Females and Males of Reproductive Potential
`
`8.4 Pediatric Use
`
`8.5 Geriatric Use
`
`8.6 Renal Impairment
`
`8.7 Hepatic Impairment
`10 OVERDOSAGE
`11 DESCRIPTION
`12 CLINICAL PHARMACOLOGY
`
`12.1 Mechanism of Action
`
`12.2 Pharmacodynamics
`
`12.3 Pharmacokinetics
`
`12.4 Microbiology
`13 NONCLINICAL TOXICOLOGY
`
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`14 CLINICAL STUDIES
`
`14.1 Description of Clinical Trials
`
`14.2 Clinical Trials in Subjects with Genotype 1 HCV
`
`14.3 Clinical Trials in Subjects with Genotype 4, 5, or 6 HCV
`
`14.4 Clinical Trials in Subjects Coinfected with HCV and HIV-1
`
`14.5 Clinical Trials in Liver Transplant Recipients and/or Subjects with
`Decompensated Cirrhosis
`14.6 Clinical Trials in Adults with Severe Renal Impairment, Including
`those Requiring Dialysis
`14.7 Clinical Trial in Pediatric Subjects
`
`16 HOW SUPPLIED/STORAGE AND HANDLING
`17 PATIENT COUNSELING INFORMATION
`* Sections or subsections omitted from the full prescribing information are not
`listed.
`
`
`
`
`
`2
`
`
`
`FULL PRESCRIBING INFORMATION
`WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS
`COINFECTED WITH HCV AND HBV
`
`
`Test all patients for evidence of current or prior hepatitis B virus (HBV) infection
`before initiating treatment with HARVONI. HBV reactivation has been reported in
`HCV/HBV coinfected patients who were undergoing or had completed treatment
`with HCV direct acting antivirals and were not receiving HBV antiviral therapy.
`Some cases have resulted in fulminant hepatitis, hepatic failure, and death.
`Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation
`during HCV treatment and post-treatment follow-up. Initiate appropriate patient
`management for HBV infection as clinically indicated [see Warnings and
`Precautions (5.1)].
`
`INDICATIONS AND USAGE
`1
`HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age
`and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and
`2.3) and Clinical Studies (14)]:
`• genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
`• genotype 1 infection with decompensated cirrhosis, for use in combination with
`ribavirin
`• genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or
`with compensated cirrhosis, for use in combination with ribavirin
`
`DOSAGE AND ADMINISTRATION
`2
`Testing Prior to the Initiation of Therapy
`2.1
`Test all patients for evidence of current or prior HBV infection by measuring hepatitis B
`surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV
`treatment with HARVONI [see Warnings and Precautions (5.1)].
`2.2 Recommended Treatment Regimen and Duration in Patients 3 Years of Age
`and Older with Genotype 1, 4, 5, or 6 HCV
`Table 1 shows the recommended HARVONI treatment regimen and duration based on
`patient population. Relapse rates are affected by baseline host and viral factors and
`differ between treatment durations for certain subgroups [see Clinical Studies (14)].
`For patients with HCV/HIV-1 coinfection, follow the dosage recommendations in Table 1
`[see Clinical Studies (14)]. Refer to Drug Interactions (7) for dosage recommendations
`for concomitant HIV-1 antiviral drugs.
`
`
`
`
`
`Reference ID: 4520919
`
`3
`
`
`
`Table 1
`
`Recommended Treatment Regimen and Duration for HARVONI in
`Patients 3 Years of Age and Older with Genotype 1, 4, 5, or 6 HCV
`Treatment Regimen and
`HCV Genotype
`Patient Population
`Duration
`
`Treatment-naïve without cirrhosis or with
`compensated cirrhosis (Child-Pugh A)
`
`HARVONI 12 weeksa
`
`Treatment-experiencedb without cirrhosis
`
`HARVONI 12 weeks
`
`HARVONI 24 weeksc
`
`HARVONI + ribavirind 12 weeks
`
`HARVONI + ribavirind 12 weeks
`
`HARVONI 12 weeks
`
`Genotype 1
`
`Genotype 1 or 4
`
`Genotype 4, 5, or 6
`
`Treatment-experiencedb with
`compensated cirrhosis (Child-Pugh A)
`Treatment-naïve and treatment-
`experiencedb with decompensated
`cirrhosis (Child-Pugh B or C)
`Treatment-naïve and treatment-
`experiencedb liver transplant recipients
`without cirrhosis, or with compensated
`cirrhosis (Child-Pugh A)
`Treatment-naïve and treatment-
`experiencedb, without cirrhosis or with
`compensated cirrhosis (Child-Pugh A)
`a. HARVONI for 8 weeks can be considered in treatment-naïve genotype 1 patients without cirrhosis
`who have pretreatment HCV RNA less than 6 million IU/mL [see Clinical Studies (14.2)].
`b. Treatment-experienced adult and pediatric subjects have failed a peginterferon alfa +/- ribavirin based
`regimen with or without an HCV protease inhibitor.
`c. HARVONI + ribavirin for 12 weeks can be considered in treatment-experienced genotype 1 patients
`with cirrhosis who are eligible for ribavirin [see Dosage and Administration (2.3 and 2.4) and Clinical
`Studies (14.2)].
`d. See Dosage and Administration 2.3 and 2.4 for ribavirin dosage recommendations.
`
`2.3 Recommended Dosage in Adults
`The recommended dosage of HARVONI in adults with genotype 1, 4, 5, or 6 HCV is
`one tablet (90 mg ledipasvir and 400 mg sofosbuvir) taken orally once daily with or
`without food [see Clinical Pharmacology (12.3)].
`The daily dosage of ribavirin is weight-based (1000 mg for patients <75 kg and 1200 mg
`for those ≥75 kg) administered orally in two divided doses with food.
`In patients with decompensated cirrhosis, the starting dosage of ribavirin is 600 mg and
`can be titrated up to 1000 mg for patients <75 kg and 1200 mg for those ≥75 kg in two
`divided doses with food. If the starting dosage of ribavirin is not well tolerated, the
`dosage should be reduced as clinically indicated based on hemoglobin levels.
`For further information on ribavirin dosing and dosage modifications, refer to the
`ribavirin prescribing information [see Dosage and Administration (2.4), Use in Specific
`Populations (8.6), and Clinical Studies (14.5)].
`
`
`
`
`Reference ID: 4520919
`
`4
`
`
`
`2.4 Recommended Dosage in Pediatric Patients 3 Years of Age and Older
`The recommended dosage of HARVONI in pediatric patients 3 years of age and older
`with genotype 1, 4, 5, or 6 HCV using HARVONI tablets or oral pellets is based on
`weight (Table 2). Table 3 provides the weight-based dosage of ribavirin when used in
`combination with HARVONI for pediatric patients. Take HARVONI tablets or pellets
`(with or without food) once daily [see Dosage and Administration (2.5), Clinical
`Pharmacology (12.3), and Clinical Studies (14.7)]. HARVONI pellets can be taken in
`pediatric patients who cannot swallow the tablet formulation.
`Table 2
`Dosing for Pediatric Patients 3 Years and Older Using HARVONI
`Tablets or Oral Pellets
`Body Weight
`(kg)
`
`HARVONI Daily Dose
`
`Dosing of HARVONI Tablets or Oral Pellets
`one 90 mg/400 mg tablet once daily
`or
`two 45 mg/200 mg tablets once daily
`or
`two 45 mg/200 mg packets of pellets once daily
`one 45 mg/200 mg tablet once daily
`or
`one 45 mg/200 mg packet of pellets once daily
`one 33.75 mg/150 mg packet of pellets once
`daily
`
`90 mg/400 mg per day
`
`45 mg/200 mg per day
`
`33.75 mg/150 mg per day
`
`at least 35
`
`17 to less than
`35
`
`less than17
`
`
`Table 3
`
`Recommended Dosing for Ribavirin in Combination Therapy with
`HARVONI for Pediatric Patients 3 Years and Older
`Body Weight (kg)
`Oral Ribavirin Daily Dosagea
`15 mg per kg per day
`(divided dose AM and PM)
`600 mg per day
`(1 x 200 mg AM, 2 x 200 mg PM)
`800 mg per day
`(2 x 200 mg AM, 2 x 200 mg PM)
`1000 mg per day
`(2 x 200 mg AM, 3 x 200 mg PM)
`1200 mg per day
`(3 x 200 mg AM, 3 x 200 mg PM)
`a. The daily dosage of ribavirin is weight-based and is administered orally in two divided doses with food.
`
`
`
`less than 47
`
`47–49
`
`50–65
`
`66–80
`
`greater than 80
`
`
`
`Reference ID: 4520919
`
`5
`
`
`
`2.5 Preparation and Administration of Oral Pellets
`Do not chew HARVONI pellets. If HARVONI pellets are administered with food, sprinkle
`the pellets on one or more spoonfuls of non-acidic soft food at or below room
`temperature. Examples of non-acidic foods include pudding, chocolate syrup, mashed
`potato, and ice cream. Take HARVONI pellets within 30 minutes of gently mixing with
`food and swallow the entire contents without chewing to avoid a bitter aftertaste.
`2.6 Renal Impairment
`No dosage adjustment of HARVONI is recommended in patients with any degree of
`renal impairment, including end stage renal disease (ESRD) on dialysis [see Dosage
`and Administration (2.3)]. Take HARVONI with or without ribavirin according to the
`recommendations in Table 1 [see Adverse Reactions (6.1), Use in Specific Populations
`(8.6), and Clinical Studies (14.6)]. Refer to ribavirin tablet prescribing information for
`ribavirin dosage modification for patients with CrCl less than or equal to 50 mL per
`minute.
`
`DOSAGE FORMS AND STRENGTHS
`3
`HARVONI is available as tablets or pellets for oral use. Each dosage form is available in
`two dose strengths.
`• 90 mg/400 mg Tablets: orange, diamond-shaped, film-coated tablet debossed
`with “GSI” on one side and “7985” on the other side of the tablet. Each tablet
`contains 90 mg ledipasvir and 400 mg sofosbuvir.
`• 45 mg/200 mg Tablets: white, capsule-shaped, film-coated tablets, debossed
`with “GSI” on one side and “HRV” on the other side. Each tablet contains 45 mg
`ledipasvir and 200 mg sofosbuvir.
`• 45 mg/200 mg Pellets: orange pellets in unit-dose packets. Each packet contains
`45 mg ledipasvir and 200 mg sofosbuvir.
`• 33.75 mg/150 mg Pellets: orange pellets in unit-dose packets. Each packet
`contains 33.75 mg ledipasvir and 150 mg sofosbuvir.
`
`CONTRAINDICATIONS
`4
`If HARVONI is administered with ribavirin, the contraindications to ribavirin also apply to
`this combination regimen. Refer to the ribavirin prescribing information for a list of
`contraindications for ribavirin [see Dosage and Administration (2.2)].
`
`WARNINGS AND PRECAUTIONS
`5
`5.1 Risk of Hepatitis B Virus Reactivation in Patients Coinfected with HCV and
`HBV
`Hepatitis B virus (HBV) reactivation has been reported in HCV/HBV coinfected patients
`who were undergoing or had completed treatment with HCV direct acting antivirals, and
`who were not receiving HBV antiviral therapy. Some cases have resulted in fulminant
`hepatitis, hepatic failure, and death. Cases have been reported in patients who are
`HBsAg positive and also in patients with serologic evidence of resolved HBV infection
`
`
`
`Reference ID: 4520919
`
`6
`
`
`
`(i.e., HBsAg negative and anti-HBc positive). HBV reactivation has also been reported
`in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk
`of HBV reactivation associated with treatment with HCV direct-acting antivirals may be
`increased in these patients.
`HBV reactivation is characterized as an abrupt increase in HBV replication manifesting
`as a rapid increase in serum HBV DNA level. In patients with resolved HBV infection,
`reappearance of HBsAg can occur. Reactivation of HBV replication may be
`accompanied by hepatitis, i.e., increases in aminotransferase levels and, in severe
`cases, increases in bilirubin levels, liver failure, and death can occur.
`Test all patients for evidence of current or prior HBV infection by measuring HBsAg and
`anti-HBc before initiating HCV treatment with HARVONI. In patients with serologic
`evidence of HBV infection, monitor for clinical and laboratory signs of hepatitis flare or
`HBV reactivation during HCV treatment with HARVONI and during post-treatment
`follow-up. Initiate appropriate patient management for HBV infection as clinically
`indicated.
`5.2 Serious Symptomatic Bradycardia When Coadministered with Amiodarone
`Postmarketing cases of symptomatic bradycardia, as well as fatal cardiac arrest and
`cases requiring pacemaker intervention, have been reported when amiodarone is
`coadministered with HARVONI. Bradycardia has generally occurred within hours to
`days, but cases have been observed up to 2 weeks after initiating HCV treatment.
`Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or
`advanced liver disease, may be at increased risk for symptomatic bradycardia with
`coadministration of amiodarone. Bradycardia generally resolved after discontinuation of
`HCV treatment. The mechanism for this effect is unknown.
`Coadministration of amiodarone with HARVONI is not recommended. For patients
`taking amiodarone who have no other alternative, viable treatment options and who will
`be coadministered HARVONI:
`• Counsel patients about the risk of serious symptomatic bradycardia
`• Cardiac monitoring in an in-patient setting for the first 48 hours of
`coadministration is recommended, after which outpatient or self-monitoring of the
`heart rate should occur on a daily basis through at least the first 2 weeks of
`treatment.
`Patients who are taking HARVONI who need to start amiodarone therapy due to no
`other alternative, viable treatment options should undergo similar cardiac monitoring as
`outlined above.
`Due to amiodarone’s long half-life, patients discontinuing amiodarone just prior to
`starting HARVONI should also undergo similar cardiac monitoring as outlined above.
`Patients who develop signs or symptoms of bradycardia should seek medical evaluation
`immediately. Symptoms may include near-fainting or fainting, dizziness or
`lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest
`pains, confusion, or memory problems [see Adverse Reactions (6.2), Drug Interactions
`(7.2)].
`
`
`
`Reference ID: 4520919
`
`7
`
`
`
`5.3 Risk of Reduced Therapeutic Effect Due to Use with P-gp Inducers
`The concomitant use of HARVONI and P-gp inducers may significantly decrease
`ledipasvir and sofosbuvir plasma concentrations and may lead to a reduced therapeutic
`effect of HARVONI. Therefore, the use of HARVONI with P-gp inducers (e.g., rifampin,
`St. John’s wort) is not recommended [see Drug Interactions (7.2)].
`5.4 Risks Associated with Ribavirin Combination Treatment
`If HARVONI is administered with ribavirin, the warnings and precautions for ribavirin, in
`particular the pregnancy avoidance warning, apply to this combination regimen. Refer to
`the ribavirin prescribing information for a full list of the warnings and precautions for
`ribavirin [see Dosage and Administration (2.2)].
`
`ADVERSE REACTIONS
`6
`The following serious adverse reactions are described below and elsewhere in labeling:
`• Serious Symptomatic Bradycardia When Coadministered with Amiodarone [see
`Warnings and Precautions (5.2)].
`6.1 Clinical Trials Experience
`Because clinical trials are conducted under widely varying conditions, adverse reaction
`rates observed in the clinical trials of a drug cannot be directly compared to rates in the
`clinical trials of another drug and may not reflect the rates observed in practice.
`If HARVONI is administered with ribavirin to adults, refer to the prescribing information
`for ribavirin for a description of ribavirin-associated adverse reactions.
`Clinical Trials in Adult Subjects
`The safety assessment of HARVONI was based on pooled data from three randomized,
`open-label Phase 3 clinical trials (ION-3, ION-1, and ION-2) of subjects with genotype 1
`HCV with compensated liver disease (with and without cirrhosis) including 215, 539,
`and 326 subjects who received HARVONI once daily by mouth for 8, 12, and 24 weeks,
`respectively [see Clinical Studies (14)].
`The proportion of subjects who permanently discontinued treatment due to adverse
`events was 0%, less than 1%, and 1% for subjects receiving HARVONI for 8, 12, and
`24 weeks, respectively.
`The most common adverse reactions (at least 10%) were fatigue and headache in
`subjects treated with 8, 12, or 24 weeks of HARVONI.
`Table 4 lists adverse reactions (adverse events assessed as causally related by the
`investigator, all grades) observed in at least 5% of subjects receiving 8, 12, or 24 weeks
`of treatment with HARVONI in clinical trials. The majority of adverse reactions
`presented in Table 4 occurred at severity of grade 1. The side-by-side tabulation is to
`simplify presentation; direct comparison across trials should not be made due to
`differing trial designs.
`
`
`
`Reference ID: 4520919
`
`8
`
`
`
`
`
`Table 4
`
`Adverse Reactions (All Grades) Reported in ≥5% of Subjects
`Receiving 8, 12, or 24 Weeks of Treatment with HARVONI
`HARVONI
`HARVONI
`HARVONI
`8 weeks
`12 weeks
`24 weeks
`(N=215)
`(N=539)
`(N=326)
`16%
`13%
`18%
`Fatigue
`11%
`14%
`17%
`Headache
`6%
`7%
`9%
`Nausea
`4%
`3%
`7%
`Diarrhea
`3%
`5%
`6%
`Insomnia
`The safety assessment of HARVONI was also based on pooled data from three open-
`label trials (Study 1119, ION-4, and ELECTRON-2) in 118 subjects with chronic HCV
`genotype 4, 5, or 6 infection with compensated liver disease (with or without cirrhosis)
`[see Clinical Studies (14.3)]. The subjects received HARVONI once daily by mouth for
`12 weeks. The safety profile in subjects with chronic HCV genotype 4, 5, or 6 infection
`with compensated liver disease was similar to that observed in subjects with chronic
`HCV genotype 1 infection with compensated liver disease. The most common adverse
`reactions occurring in at least 10% of subjects were asthenia (18%), headache (14%),
`and fatigue (10%).
`Adverse Reactions in Subjects with Cirrhosis
`The safety assessment of HARVONI with or without ribavirin was based on a
`randomized, double-blind and placebo-controlled trial in treatment-experienced
`genotype 1 subjects with compensated cirrhosis and was compared to placebo in the
`SIRIUS trial. Subjects were randomized to receive 24 weeks of HARVONI once daily by
`mouth without ribavirin or 12 weeks of placebo followed by 12 weeks of HARVONI once
`daily by mouth + ribavirin [see Clinical Studies (14.2)]. Table 5 presents the adverse
`reactions, as defined above, that occurred with at least 5% greater frequency in
`subjects treated with 24 weeks of HARVONI or 12 weeks of HARVONI + ribavirin,
`compared to those reported for 12 weeks of placebo. The majority of the adverse
`reactions presented in Table 5 were Grade 1 or 2 in severity.
`
`
`
`
`Reference ID: 4520919
`
`9
`
`
`
`Table 5
`
`
`
`Adverse Reactions with ≥5% Greater Frequency Reported in
`Treatment-Experienced Subjects with Cirrhosis Receiving HARVONI
`for 24 Weeks or HARVONI + Ribavirin for 12 Weeks Compared to
`Placebo for 12 weeks
`HARVONI
`24 weeks
`(N=78)
`31%
`29%
`18%
`5%
`9%
`3%
`8%
`5%
`
`HARVONI + RBV
`12 weeks
`(N=76)
`36%
`13%
`4%
`11%
`4%
`9%
`7%
`1%
`
`Placebo
`12 weeks
`(N=77)
`23%
`16%
`1%
`1%
`0
`1%
`1%
`0
`
`Asthenia
`Headache
`Fatigue
`Cough
`Myalgia
`Dyspnea
`Irritability
`Dizziness
`RBV=ribavirin
`
`Adverse Reactions in Subjects Coinfected with HIV-1
`The safety assessment of HARVONI was based on an open-label clinical trial in
`335 genotype 1 or 4 subjects with HCV/HIV-1 coinfection who were on stable
`antiretroviral therapy in Study ION-4 [see Clinical Studies (14.4)]. The safety profile in
`HCV/HIV-1 coinfected subjects was similar to that observed in HCV mono-infected
`subjects. The most common adverse reactions occurring in at least 10% of subjects
`were headache (20%) and fatigue (17%).
`Adverse Reactions in Liver Transplant Recipients and/or Subjects with Decompensated
`Cirrhosis
`The safety assessment of HARVONI with ribavirin in liver transplant recipients and/or
`those who had decompensated liver disease was based on pooled data from two Phase
`2 open-label clinical trials including 336 subjects who received HARVONI plus ribavirin
`for 12 weeks. Subjects with Child-Pugh-Turcotte (CPT) scores greater than 12 were
`excluded from the trials [see Clinical Studies (14.5)].
`The adverse events observed were consistent with the expected clinical sequelae of
`liver transplantation and/or decompensated liver disease, or the known safety profile of
`HARVONI and/or ribavirin.
`Decreases in hemoglobin to less than 10 g/dL and 8.5 g/dL during treatment were
`observed in 38% and 13% of subjects treated with HARVONI plus ribavirin for 12
`weeks, respectively. Ribavirin was permanently discontinued in 11% of subjects treated
`with HARVONI plus ribavirin for 12 weeks.
`
`
`
`Reference ID: 4520919
`
`10
`
`
`
`Liver Transplant Recipients with Compensated Liver Disease:
`Among the 174 liver transplant recipients with compensated liver disease who received
`HARVONI with ribavirin for 12 weeks, 2 (1%) subjects permanently discontinued
`HARVONI due to an adverse event.
`
`Subjects with Decompensated Liver Disease:
`Among the 162 subjects with decompensated liver disease (pre- or post-transplant) who
`received HARVONI with ribavirin for 12 weeks, 7 (4%) subjects died, 4 (2%) subjects
`underwent liver transplantation, and 1 subject (<1%) underwent liver transplantation and
`died during treatment or within 30 days after discontinuation of treatment. Because
`these events occurred in patients with advanced liver disease who are at risk of
`progression of liver disease including liver failure and death, it is not possible to reliably
`assess the contribution of drug effect to outcomes. A total of 4 (2%) subjects
`permanently discontinued HARVONI due to an adverse event.
`Less Common Adverse Reactions Reported in Clinical Trials (less than 5%): The
`following adverse reactions occurred in less than 5% of subjects receiving HARVONI in
`any one trial. These events have been included because of their seriousness or
`assessment of potential causal relationship.
`Psychiatric disorders: depression (including in subjects with pre-existing history of
`psychiatric illness).
`Depression (particularly in subjects with pre-existing history of psychiatric illness)
`occurred in subjects receiving sofosbuvir containing regimens. Suicidal ideation and
`suicide have occurred in less than 1% of subjects treated with sofosbuvir in
`combination with ribavirin or pegylated interferon/ribavirin in other clinical trials.
`Laboratory Abnormalities
`Bilirubin Elevations: Bilirubin elevations of greater than 1.5xULN were observed in
`3%, less than 1%, and 2% of subjects treated with HARVONI for 8, 12, and
`24 weeks, respectively. Bilirubin elevations of greater than 1.5xULN were observed
`in 3%, 11%, and 3% of subjects with compensated cirrhosis treated with placebo,
`HARVONI + ribavirin for 12 weeks, and HARVONI for 24 weeks, respectively, in the
`SIRIUS trial.
`Lipase Elevations: Transient, asymptomatic lipase elevations of greater than 3xULN
`were observed in less than 1%, 2%, and 3% of subjects treated with HARVONI for 8,
`12, and 24 weeks, respectively. Transient, asymptomatic lipase elevations of greater
`than 3x ULN were observed in 1%, 3%, and 9% of subjects with compensated
`cirrhosis treated with placebo, HARVONI + ribavirin for 12 weeks, and HARVONI for
`24 weeks, respectively, in the SIRIUS trial.
`Creatine Kinase: Creatine kinase was not assessed in Phase 3 trials ION-3, ION-1,
`or ION-2 of HARVONI. Creatine kinase was assessed in the ION-4 trial. Isolated,
`asymptomatic creatine kinase elevations of greater than or equal to 10xULN was
`observed in 1% of subjects treated with HARVONI for 12 weeks in the ION-4 trial
`
`
`
`Reference ID: 4520919
`
`11
`
`
`
`and has also been previously reported in subjects treated with sofosbuvir in
`combination with ribavirin or peginterferon/ribavirin in other clinical trials.
`Adverse Reactions in Adults with Severe Renal Impairment, Including those on Dialysis
`In an open-label trial (Trial 0154) in which adults with HCV with compensated liver
`disease (with or without cirrhosis) and severe renal impairment received HARVONI for
`12 weeks (N=18), the most common adverse reaction was fatigue (17%) [see Clinical
`Studies (14.6)].
`In an open-label clinical trial, Trial 4063, a total of 95 adults with HCV with compensated
`liver disease (with or without cirrhosis) and ESRD requiring dialysis received HARVONI
`for 8 (n=45), 12 (n=31), or 24 (n=19) weeks. The most common adverse reactions were
`insomnia and headache (each reported in 4% of subjects overall) [see Clinical Studies
`(14.6)].
`Adverse Reactions in Pediatric Subjects 3 Years of Age and Older
`The safety assessment of HARVONI in pediatric subjects 3 years of age and older is
`based on data from a Phase 2, open-label clinical trial (Study 1116). In total, 226
`subjects were enrolled, which included 223 subjects without cirrhosis or with
`compensated cirrhosis who w